LAS VEGAS, Oct. 16, 2024
The PARP inhibitors market is anticipated to experience substantial growth in the coming years. This growth is driven by label expansion of leading PARP inhibitors in various indications, a rising number of cancer diagnoses mainly metastatic breast, ovarian, prostate, and pancreatic cancers, heightened awareness of HRR gene mutation testing (mainly BRCA mutation testing ), along with an evolving pipeline of newer treatments.
Advertisement
LAS VEGAS, Oct. 16, 2024 /PRNewswire/ -- DelveInsight's PARP Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging PARP inhibitors, market share of individual therapies, and current and forecasted PARP inhibitors market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Advertisement
Key Takeaways from the PARP Inhibitors Market Report
Discover which therapies are expected to grab the PARP inhibitors market share @ PARP Inhibitors Market Report
PARP Inhibitors Market Dynamics
The PARP inhibitors market has seen significant growth and transformation in recent years, driven primarily by advancements in oncology and the increasing recognition of these drugs' therapeutic potential. One of the key dynamics in the PARP inhibitors market is the increasing prevalence of cancer and the growing demand for targeted therapies. As the global incidence of cancer rises, there is a significant push towards more personalized and effective treatment options. PARP inhibitors have shown promise in clinical trials for various cancers beyond those with BRCA mutations, including pancreatic and non-small cell lung cancers, which broadens their market potential. This expansion into new indications enhances the overall market opportunity and drives further research and development.
Moreover, the competitive landscape is evolving as pharmaceutical companies invest heavily in the development of next-generation PARP inhibitors. Companies are not only working on improving the efficacy and safety profiles of existing drugs but are also exploring combination therapies that could enhance treatment outcomes. Strategic partnerships, mergers, and acquisitions in the industry are contributing to rapid advancements and commercialization of new products, which in turn affects market dynamics.
Additionally, regulatory pathways and reimbursement policies play a crucial role in shaping the market. The approval process for new therapies can be lengthy and complex, and regulatory bodies' decisions significantly impact market entry and adoption. Furthermore, the level of insurance coverage and reimbursement for PARP inhibitors influences their accessibility and affordability, impacting market growth. As policies evolve and more data becomes available, these factors will continue to influence the market's trajectory.
PARP Inhibitors Treatment Market
So far, the approved PARP inhibitors are LYNPARZA (olaparib), TALZENNA (talazoparib), ZEJULA (niraparib), and RUBRACA (rucaparib), with LYNPARZA currently leading the market. PARP inhibitor monotherapy has been a breakthrough in treating many BRCA1/2-mutated cancers, providing both patients and doctors with promising treatment options. Research continues into alternative therapeutic pathways for PARP inhibitors, as well as understanding the mechanisms behind sensitivity and resistance. Identifying biomarkers is crucial for determining which patients will benefit most since while these treatments are effective in tumors with BRCA1/2 mutations or HRD, reliable HR-proficient markers are still needed.
GSK's decision to restrict ZEJULA's use in the US to only patients with germline BRCA mutations, while withdrawing its approval for late-line ovarian cancer, could have far-reaching consequences in the PARP inhibitor market. This move might impact other PARP inhibitors, such as LYNPARZA by AstraZeneca and Merck, and RUBRACA by Clovis Oncology.
Currently, RUBRACA's main revenue comes from its use as a second-line maintenance treatment for ovarian cancer. Any restrictions on this indication could significantly heighten Clovis's risk of bankruptcy. TALZENNA is emerging as a potential competitor to established PARP inhibitors like LYNPARZA and ZEJULA, thanks to promising clinical trial results. Its effectiveness in treating mCRPC may also benefit from its combination with Xtandi, a leading prostate cancer treatment.
Learn more about the FDA-approved PARP inhibitors @ PARP Inhibitors Drugs
Key Emerging PARP Inhibitors and Companies
Several key players, including AstraZeneca, Allarity Therapeutics, AtlasMedx, BeiGene, and others, are involved in developing drugs for PARP inhibitors for various indications such as ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and others.
Saruparib (AZD5305), a next-generation PARP1-selective inhibitor, is being tested in patients with tumors that have specific homologous recombination repair gene mutations. This drug is designed to precisely target PARP1, disrupting cancer cells by interfering with their DNA damage repair mechanisms. This strategy may enable PARP inhibitors to be used in new therapeutic settings and to be combined with other agents that activate DNA damage pathways, such as ADCs.
Saruparib (AZD5305) is advancing towards potential registrational trials for prostate cancer, in combination with new hormonal therapies, with studies showing good tolerability at higher doses. The drug is currently being evaluated in clinical trials for patients with advanced solid tumors, including ovarian, breast, prostate, and pancreatic cancers.
Veliparib (ABT-888) is an experimental anti-cancer drug that functions as a PARP inhibitor. It works by blocking the PARP protein, which disrupts the repair of DNA damage in cancer cells, potentially increasing their vulnerability to anticancer therapies. Veliparib inhibits both PARP1 and PARP2, leading to synthetic lethality. The drug is currently under investigation for its effectiveness in treating solid tumors.
The anticipated launch of these emerging therapies are poised to transform the PARP inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the PARP inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about PARP inhibitors clinical trials, visit @ PARP Inhibitors Treatment Drugs
PARP Inhibitors Overview
PARP inhibitors are a class of drugs that target the enzyme Poly (ADP-ribose) polymerase (PARP), which plays a crucial role in DNA repair processes, particularly in repairing single-strand breaks. By inhibiting PARP, these drugs prevent the repair of damaged DNA, leading to the accumulation of DNA breaks, which eventually causes cancer cells to die. This mechanism is particularly effective in tumors with deficiencies in other DNA repair pathways, such as those with BRCA1 or BRCA2 mutations, making PARP inhibitors a powerful targeted therapy for certain types of cancers, including ovarian, breast, and prostate cancers.
One of the key advantages of PARP inhibitors is their ability to selectively target cancer cells while sparing normal cells, reducing some of the side effects associated with traditional chemotherapy. However, like many targeted therapies, resistance to PARP inhibitors can develop over time, posing challenges for long-term treatment efficacy. Despite this, ongoing research is exploring combination therapies and new strategies to overcome resistance, further expanding the potential of PARP inhibitors in cancer treatment.
PARP Inhibitors Epidemiology Segmentation
The total incident cases of breast cancer in the US comprised approximately 297,000 cases in 2023. In 2023, in the United States, the total cases of metastatic castration-sensitive prostate cancer and metastatic castration-resistant prostate cancer were around 54,200 and 66,200, respectively.
The PARP inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
PARP Inhibitors Report Metrics
Details
Study Period
2020–2034
PARP Inhibitors Report Coverage
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key PARP Inhibitors Companies
AstraZeneca/Merck, Janssen, Pfizer/Astellas, Pharma& Schweiz, AtlasMedx, AbbVie, GlaxoSmithKline, Pfizer, BeiGene, Allarity Therapeutics, and others
Key PARP Inhibitors
LYNPARZA, ZEJULA, RUBRACA, TALZENNA, AKEEGA, Saruparib (AZD5305), AMXI-5001, Veliparib and others
Scope of the PARP Inhibitors Market Report
Discover more about PARP inhibitors in development @ PARP Inhibitors Clinical Trials
Table of Contents
1
Key Insights
2
Report Introduction
3
Executive Summary of PARP Inhibitors
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
PARP Inhibitors Market Overview at a Glance in the 7MM
6.1
Market Share (%) Distribution by Indication in 2023
6.2
Market Share (%) Distribution by Indication in 2034
7
PARP Inhibitors: Background and Overview
7.1
Introduction
7.2
Types of PARP inhibitors
7.3
Treatment
8
Target Patient Pool
8.1
Key Findings
8.2
Assumptions and Rationale: 7MM
8.3
Epidemiology Scenario in the 7MM
8.3.1
Total Incident Cases in Selected Indications for PARP Inhibitors in the 7MM
8.3.2
Total Eligible Patient Pool for PARP Inhibitors in Selected Indications in the 7MM
8.3.3
Total Treated Cases in Selected Indications for PARP Inhibitors in the 7MM
9
Marketed Therapies
9.1
Key Competitors
9.2
LYNPARZA: AstraZeneca
9.2.1
Product description
9.2.2
Regulatory milestones
9.2.3
Other developmental activities
9.2.4
Clinical development
9.2.5
Safety and efficacy
9.3
ZEJULA: GlaxoSmithKline
9.3.1
Product description
9.3.2
Regulatory milestones
9.3.3
Other developmental activities
9.3.4
Clinical development
9.3.5
Safety and efficacy
9.4
RUBRACA: Pharma& Schweiz GmbH
9.4.1
Product description
9.4.2
Regulatory milestones
9.4.3
Other developmental activities
9.4.4
Clinical development
9.4.5
Safety and efficacy
9.5
TALZENNA: Pfizer
9.5.1
Product description
9.5.2
Regulatory milestones
9.5.3
Other developmental activities
9.5.4
Clinical development
9.5.5
Safety and efficacy
List to be continued in the report
10
Emerging Therapies
10.1
Key Competitors
10.2
AZD5305: AstraZeneca
10.2.1
Product description
10.2.2
Other developmental activities
10.2.3
Clinical development
10.2.4
Safety and efficacy
10.3
Veliparib: AbbVie
10.3.1
Product description
10.3.2
Other developmental activities
10.3.3
Clinical development
10.3.4
Safety and efficacy
List to be continued in the report
11
PARP Inhibitors: Seven Major Market Analysis
11.1
Key Findings
11.2
Market Outlook
11.3
Key Market Forecast Assumptions
11.3.1
Cost Assumptions and Rebates
11.3.2
Pricing Trends
11.3.3
Analogue Assessment
11.3.4
Launch Year and Therapy Uptakes
11.4
Total Market Size by Indication in the 7MM
11.5
Total Market Size by Therapies in the 7MM
11.6
The United States Market Size
11.6.1
Total Market Size by Indication in the United States
11.6.2
Total Market Size by Therapies in the United States
11.7
EU4 and the UK Market Size
11.7.1
Total Market Size by Indication in EU4 and the UK
11.7.2
Total Market Size by Therapies in EU4 and the UK
11.8
Japan Market Size
11.8.1
Total Market Size by Indication in Japan
11.8.2
Total Market Size by Therapies in Japan
12
Market Access and Reimbursement
13
SWOT Analysis
14
KOL Views
15
Unmet Needs
16
Appendix
16.1
Bibliography
16.2
Report Methodology
17
DelveInsight Capabilities
18
Disclaimer
19
About DelveInsight
Related Reports
Prostate Cancer Market
Prostate Cancer Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key prostate cancer companies, including Proteomedix, A3P Biomedical, GE HealthCare, Soteria Medical BV, Bio-Techne, F. Hoffmann-La Roche Ltd., Indica Labs Inc., OPKO HEALTH, INC., miR Scientific, LLC, MINOMIC®, Novartis AG, Johnson and Johnson Services, Inc., Astellas Pharma Inc., Cipla, AstraZeneca, Bayer AG, Zydus Cadila, Pfizer Inc., Avenda Health, The Sanpower Group, among others.
Metastatic Prostate Cancer Market
Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others.
Breast Cancer Market
Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key breast cancer companies including Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, Daiichi Sankyo, among others.
Ovarian Cancer Market
Ovarian Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key ovarian cancer companies including Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co, Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, VBL Therapeutics, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur [email protected] +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/parp-inhibitors-market-to-register-immense-growth-by-2034-owing-to-wider-opportunity-in-multiple-indications-with-hrr-brca-gene-mutations-and-increasing-cost-of-therapy-of-leading-parp-inhibitors-in-the-us--delveinsight-302277360.html
SOURCE DelveInsight Business Research, LLP
